Monitor for any definitive government procurement or funding agreements with BARDA or allied nations, which would be a significant catalyst. Absent that, the stock remains speculative with no near-term revenue visibility.
Price Chart
Executive Summary
Valion Bio provided a business update on its Entolimod platform, highlighting continued government engagement with BARDA/NIAID/AFRRI, a 200-fold manufacturing scale-up, and planned expansion into oncology supportive care. No financial results or binding agreements were disclosed; the filing is a routine operational update.
Key Facts
- Continued discussions with BARDA, NIAID, AFRRI, and U.S. Department of War for potential development support and Strategic National Stockpile opportunities.
- Demonstrated approximately 200-fold manufacturing scale-up of Entolimod to 50-liter fermentation scale, equivalent to ~1.3 million potential human doses.
- Advanced preparations for physician-sponsored studies in neutropenia as first oncology supportive care indication.
- Over $140 million invested in Entolimod development to date.
- No funding, procurement, or stockpiling agreements have been executed.
Financial Impact
No financial figures reported; over $140M invested in Entolimod historically.
Risk Factors
- No binding government agreements; discussions may not lead to procurement or funding.
- Reliance on additional capital raises; Nasdaq listing compliance risk (market cap $2M).
- Pre-revenue stage with no approved products; regulatory and clinical uncertainties.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-005497 |
| Document: valion_8k.htm | 0001683168-26-005497 |
| Document: 0001683168-26-005497-index-headers.html | 0001683168-26-005497 |
| Document: 0001683168-26-005497-index.html | 0001683168-26-005497 |
| Document: 0001683168-26-005497.txt | 0001683168-26-005497 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.8950 | awaiting T+20 | — | $0.7820 (+12.63%) |
Oct 26, 2026 1d ago | 8-K | $0.8400 | awaiting T+20 | — | $0.7820 (−6.90%) |
Oct 22, 2026 5d ago | 8-K | $0.9560 | awaiting T+20 | — | $0.7820 (−18.20%) |
Oct 21, 2026 7d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 21, 2026 7d ago | EFFECT | $1.12 | awaiting T+20 | — | $0.7820 (+30.18%) |
Oct 16, 2026 11d ago | S-3 | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 16, 2026 11d ago | DEF 14A | $1.16 | awaiting T+20 | — | $0.7820 (+32.59%) |
Oct 15, 2026 12d ago | 8-K | $1.23 | awaiting T+20 | — | $0.7820 (−36.42%) |
Oct 14, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $0.7820 (−46.07%) |
Oct 8, 2026 19d ago | 8-K | $2.21 | awaiting T+20 | — | $0.7820 (+64.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers